Jiaojiao Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiaojiao Tan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Chaofan Pan
School of Medicine, Qingdao Huanghai University, Qingdao 266427, China
1 shared publication - Jiang Li
Marine Bioresource and Environment Research Center, First Institute of Oceanography, Ministry of Natural Resources, Qingdao 266061, China
1 shared publication - Jican Han
School of Medicine, Qingdao Huanghai University, Qingdao 266427, China
1 shared publication - Jing Wang
Key Laboratory of Ocean Observation and Forecasting Key Laboratory of Ocean Circulation and Waves Institute of Oceanology Chinese Academy of Sciences Qingdao China
1 shared publication - Junjie Liu
School of Medicine, Qingdao Huanghai University, Qingdao 266427, China
1 shared publication - Lihua Geng
CAS and Shandong Province Key Laboratory of Experimental Marine Biology, Center for Ocean Mega-Science, Institute of Oceanology, Chinese Academy of Sciences, Qingdao 266071, China
1 shared publication
Latest Publications
- Open Access
Gut Microbiota-Derived SCFAs Modulated by Different Structures of Marine Algal Oligosaccharides Alleviate Colitis Through PPARγ Signaling Activation
Background: Marine algal oligosaccharide (MAO) molecular structural characteristics are closely related to their bioactivity. However, an understanding of the specific relationships between MAO molecular structure (including polymerization degree [DP] and sulfate groups) and bioactivity is lacking. Methods: In this work, laboratory-prepared DP4 and DP8 MAOs, including agar- (AOs) and κ-, ι-, and λ-carrageenan-oligosaccharides (COs), were examined for their anti-inflammatory activity in RAW264.7 macrophages and therapeutic effect on colitis in mice; additionally, the potential mechanisms involved were explored. Results: The results showed that CO (ι- and λ-COs) anti-inflammatory activity was higher than that of AOs and was positively correlated with sulfate group content. MAOs with different structures all alleviated colitis symptoms; those with higher sulfate group content and DP showed excellent therapeutic efficacy. MAOs modulated gut microbiota and promoted the enrichment of microbiota-derived short-chain fatty acid production (butyrate), which potentially induced PPARγ signaling and contributed to the impacts of MAOs on mucosal homeostasis restoration. Conclusions: Therefore, MAOs with higher sulfate content and DP showed improved therapeutic efficacy compared with those with lower contents, which involved higher SCFA production.
Open AccessGut Microbiota-Derived SCFAs Modulated by Different Structures of Marine Algal Oligosaccharides Alleviate Colitis Through PPARγ Signaling Activation
Background: Marine algal oligosaccharide (MAO) molecular structural characteristics are closely related to their bioactivity. However, an understanding of the specific relationships between MAO molecular structure (including polymerization degree [DP] and sulfate groups) and bioactivity is lacking. Methods: In this work, laboratory-prepared DP4 and DP8 MAOs, including agar- (AOs) and κ-, ι-, and λ-carrageenan-oligosaccharides (COs), were examined for their anti-inflammatory activity in RAW264.7 macrophages and therapeutic effect on colitis in mice; additionally, the potential mechanisms involved were explored. Results: The results showed that CO (ι- and λ-COs) anti-inflammatory activity was higher than that of AOs and was positively correlated with sulfate group content. MAOs with different structures all alleviated colitis symptoms; those with higher sulfate group content and DP showed excellent therapeutic efficacy. MAOs modulated gut microbiota and promoted the enrichment of microbiota-derived short-chain fatty acid production (butyrate), which potentially induced PPARγ signaling and contributed to the impacts of MAOs on mucosal homeostasis restoration. Conclusions: Therefore, MAOs with higher sulfate content and DP showed improved therapeutic efficacy compared with those with lower contents, which involved higher SCFA production.
- Open Access
- 27 February 2020
- Published by MDPI AG in Marine Drugs
- Vol. 18 (3) , 137
Comparative Study of Fucoidan from Saccharina japonica and Its Depolymerized Fragment on Adriamycin-Induced Nephrotic Syndrome in Rats
Nephrotic syndrome (NS) is a clinical syndrome with a variety of causes, mainly characterized by heavy proteinuria, hypoalbuminemia, and edema. At present, identification of effective and less toxic therapeutic interventions for nephrotic syndrome remains to be an important issue. In this study, we isolated fucoidan from Saccharina japonica and prepared its depolymerized fragment by oxidant degradation. Fucoidan and its depolymerized fragment had similar chemical constituents. Their average molecular weights were 136 and 9.5 kDa respectively. The effect of fucoidan and its depolymerized fragment on adriamycin-induced nephrotic syndrome were investigated in a rat model. The results showed that adriamycin-treated rats had heavy proteinuria and increased blood urea nitrogen (BUN), serum creatinine (SCr), total cholesterol (TC), and total triglyceride (TG) levels. Oral administration of fucoidan or low-molecular-weight fucoidan for 30 days could significantly inhibit proteinuria and decrease the elevated BUN, SCr, TG, and TC level in a dose-dependent manner. At the same dose (100 mg/kg), low-molecular-weight fucoidan had higher renoprotective activity than fucoidan. Their protective effect on nephrotic syndrome was partly related to their antioxidant activity. The results suggested that both fucoidan and its depolymerized fragment had excellent protective effect on adriamycin-induced nephrotic syndrome, and might have potential for the treatment of nephrotic syndrome.
- 27 February 2020
- Published by MDPI AG in Marine Drugs
- Vol. 18 (3) , 137
Open AccessComparative Study of Fucoidan from Saccharina japonica and Its Depolymerized Fragment on Adriamycin-Induced Nephrotic Syndrome in Rats
Nephrotic syndrome (NS) is a clinical syndrome with a variety of causes, mainly characterized by heavy proteinuria, hypoalbuminemia, and edema. At present, identification of effective and less toxic therapeutic interventions for nephrotic syndrome remains to be an important issue. In this study, we isolated fucoidan from Saccharina japonica and prepared its depolymerized fragment by oxidant degradation. Fucoidan and its depolymerized fragment had similar chemical constituents. Their average molecular weights were 136 and 9.5 kDa respectively. The effect of fucoidan and its depolymerized fragment on adriamycin-induced nephrotic syndrome were investigated in a rat model. The results showed that adriamycin-treated rats had heavy proteinuria and increased blood urea nitrogen (BUN), serum creatinine (SCr), total cholesterol (TC), and total triglyceride (TG) levels. Oral administration of fucoidan or low-molecular-weight fucoidan for 30 days could significantly inhibit proteinuria and decrease the elevated BUN, SCr, TG, and TC level in a dose-dependent manner. At the same dose (100 mg/kg), low-molecular-weight fucoidan had higher renoprotective activity than fucoidan. Their protective effect on nephrotic syndrome was partly related to their antioxidant activity. The results suggested that both fucoidan and its depolymerized fragment had excellent protective effect on adriamycin-induced nephrotic syndrome, and might have potential for the treatment of nephrotic syndrome.